



Financial Tear Sheet

Corporate Profile

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com (<http://www.alkermes.com>).

IR Contacts

Sandy Coombs
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6377
E-mail: Sandra.Coombs@alkermes.com (<mailto:Sandra.Coombs@alkermes.com>)

Eva Stroynowski
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6823
E-mail: eva.stroynowski@alkermes.com (<mailto:eva.stroynowski@alkermes.com>)

Stock Performance

ALKS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$32.57
Change (%)	0.78 (2.34%)
Volume	602,399
52 Week Low	\$27.54
Market Cap	\$5,082,197,135
Rolling EPS	-0.90
PE Ratio	N/A
Shares Outstanding	156,039,212
Data as of 02/21/19 4:00 p.m. ET	



Recent Headlines & Events

- 02/20/19 - 4:02 p.m.
Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference (phoenix.zhtml?c=92211&p=iro-newsArticle&ID=2388210)
- 02/19/19 - 7:00 a.m.
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies (phoenix.zhtml?c=92211&p=iro-newsArticle&ID=2387849)
- 02/14/19 - 7:00 a.m.
Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019 (phoenix.zhtml?c=92211&p=iro-newsArticle&ID=2387481)

Date	Title
02/27/19 2:30 p.m. ET	SVB Leerink Global Healthcare Conference (phoenix.zhtml?c=92211&p=iro-EventDetails&EventId=5277473)

Mean Recommendation: 2.9

Unable to fulfill request.



Sell Strong Buy

SEC Filings

Year Filter

All Years

Filing Date	Form
02/19/19	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTI3MjEzMDcm3Vic2lkPTU3Jml4YnJsPXRydWU%3d&ListAll=1)
02/19/19	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTI3MjEzMDcm3Vic2lkPTU3Jml4YnJsPXRydWU%3d&ListAll=1)
02/19/19	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTI3MjEzMDcm3Vic2lkPTU3Jml4YnJsPXRydWU%3d&ListAll=1)
02/19/19	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2I6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTI3MjEzMDcm3Vic2lkPTU3Jml4YnJsPXRydWU%3d&ListAll=1)

Corporate Governance

Richard F. Pops Chairman and Executive Offi

Shane Cooke President

Kathryn L. Biberstein Senior Vice Pre Chief Legal Of Chief Compliar Officer, and Se Alkermes plc

Madeline D. Coffin Vice President, Resources

Elliot W. Ehrich, M.D. Executive Vice President, Res Development, e Medical Office

James M. Frates Senior Vice Pre Chief Financia

Georgianna Harris, Ph.D. Vice President, Regulatory Aff

Blair C. Jackson Vice President, Development

Michael J. Landine Senior Vice Pre Corporate Dev

Mark Namchuk, Ph.D. Senior Vice Pre Research, Phar and Nonclinical Development

Peter Norman Vice President, Government P Affairs

Rebecca J. Peterson Senior Vice Pre Corporate Communicator

Gordon G. Pugh Senior Vice Pre Chief Operatin and Chief Risk

Srdjan Stankovic, M.D., MSPH Senior Vice Pre Clinical Develo Medical Affairs

Mark Stejbach Senior Vice Pre Chief Commer Officer

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	0	.00	0.0	0
Mutual Fund	0	.00	0.0	0
Insider *	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Powered by **EDGAR**Online Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed